ArticleBMC cancer2025

Prospective phase II study of stereotactic body proton therapy for treatment of primary renal cell carcinoma (SPARE): clinical trial protocol.

Sherif G Shaaban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.